You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Oct 30, 2026; less than a full year is stored.
Bambusa Therapeutics, Inc. filed an amended and restated certificate of incorporation and adopted amended and restated bylaws on November 2, 2026, following completion of its initial public offering.
Bambusa Therapeutics, Inc. is offering 9,375,000 common shares at an expected $15.00 to $17.00 per share and applied to list them on Nasdaq Global Select Market under “BBTX,” with closing contingent on listing.
Bambusa Therapeutics, Inc. is pursuing an initial public offering of common stock and applied to list on the Nasdaq Global Select Market under “BBTX,” subject to Nasdaq approval and an effective registration statement.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBTX
this stock
Bambusa Therapeutics, Inc.
|
$807.44M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$138.71B | +20.7% | +46.2% | 35.2 | 1.7% |
|
MRNA
Moderna, Inc.
|
$96.40B | +762.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$93.82B | +17.2% | +20.8% | 20.1 | 2.1% |
|
CSLLY
Csl Ltd
|
$67.11B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Bambusa Therapeutics, Inc. filed an amended and restated certificate of incorporation and adopted amended and restated bylaws on November 2, 2026, following completion of its initial public offering.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBTX | +4.9% | — | — | +4.9% | — |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | +7.6% | — | — | +7.6% | — |
